Analysis of IL-33 gene polymorphism (rs11792633 C/T) and risk of schizophrenia

Document Type: Short communication


1 University of sistan and Baluchestan

2 university of Ferdowssi,Mashhad, Iran


Recently, inflammation has been found to be a significant factor in the development of Schizophrenia (SCZ). The aim of the present research was to investigate whether interleukin-33 (IL-33, OMIM: 608678) gene polymorphism (rs11792633, C/T) is associated with the development of SCZ or not.DNA was isolated from the serum of 70 patients with SCZ and 70 healthy controls. The PCR based method was used for detection of the IL-33 polymorphism. The CT (OR=0.05, 95% CI: 0.003-0.057, P<0.001) andTT(OR=0.12, 95% CI: 0.028-0.46, P<0.001) genotypes significantly decreased the risk of SCZ. Our present findings indicate that the IL-33 polymorphism associated with the risk of SCZ.




Schizophrenia (SCZ) is a genetically complex mental disorder, which may affect up to 1% of the world’s population. There is some evidence suggesting that cytokine production during chronic activation of the immune system ,which is observed in SCZ, could modulate prodromes, the active  residual phases of this disease, and influence response to treatment [1, 2]. Interleukin-33 (IL-33, OMIM: 608678) is a 30kD protein with a length of 270 amino acids in two domains, a helix-turn-helix domain and an IL-1-like domain for binding to and activation of the ST2 receptors [3, 4]. IL-33 can act as either a pro-inflammatory or an anti-inflammatory cytokine [4-6]. Recently it has been described as a member of the IL-1 family. This cytokine has a dual-function with nuclear and extracellular effects [4]. The critical role of this cytokine in  allergic inflammatory diseases such as rhinitis is well known [6]. IL-33 is a ligand of the IL-1R family member ST2 (also called ST2L, T1, Der-4), which makes part of the Toll-like receptor (TLR)/IL1R super family [7]. The producers of IL-33 are different immune cells such as macrophages, dendritic cells and mast cells (in these cells, IL-33 induces the secretion of chemokines and cytokines such as IL-6, IL-8, and IL-13). In addition, some of the non-immune cells including endothelial, epithelial, smooth muscle cells and fibroblasts are producers of this cytokine [8]. Basal IL-33 mRNA levels are extremely high in the brain and spinal cord. Furthermore, the expression of IL-33 in glial and astrocyte cultures is increased by Toll-like receptor ligands. Treatment with IL-33 induces the proliferation of microglia and enhances the production of pro-inflammatory cytokines such as IL-1b and TNFα as well as the anti-inflammatory cytokine IL-10. It also enhances chemokines, along with nitric oxide production and phagocytosis by microglia [9]. A better understanding of the molecular events that occur during inflammation within the central nervous system could lead to the development of novel therapeutic strategies to treat disorders associated with activation of inflammatory pathways in the brain. The aim of the present study was to determine the association of IL-33 gene polymorphism (rs11792633, C/T) with the development of SCZ.



Materials and methods


This case-control study was approved by the Ethics Committee of Azadi Hospital, Tehran, Iran and conducted in 2010–2011. The subjects consisted of a healthy control group (n=70), who were free from any signs of neuropsychiatric diseases, and a patient group diagnosed with SCZ (n=70). Serum samples for DNA extraction were collected in tubes. For DNA extraction, a Cinnapure DNA purification kit was used. Polymorphism was identified by PCR using a Tetra Amplification Refractory Mutation System (Tetra ARMS–PCR). Sequences of primers used are listed in Table 1.

Statistical analysis was conducted using SPSS statistical software, version 16 (SPSS, Chicago, IL) and Epical version3.2. Categorical data were analyzed by Pearson’s c2 test.



Results AND Discussion


The main characteristics of the populations are described in Table 2. There were differences between cases and controls for smoking habit, educational levels, and marital status.

As shown in Table 3,CT (OR=0.05, 95% CI: 0.003-0.057, P<0.001) and TT (OR=0.12, 95% CI: 0.02-0.46, P<0.001) genotypes significantly decreased the risk of SCZ. Studies have revealed that one of the abnormalities found in SCZ includes changes in the immunological system [10].

We hypothesized that patients with SCZ may demonstrate a different distribution of allele frequencies in the IL-33 gene from controls. In this study, we have reported the significant association of rs11792633 SNP in the IL-33 and risk of SCZ in an Iranian population. IL-33 may also play a protective role in the development and progression of atherosclerosis [12]. Recently, functional studies have shown that the minor alleles, rs1157505, rs11792633, and rs7044343 within IL-33 were associated with a lower degree of cerebral amyloid angiopathy in the brains of non- apolipoprotein E, and IL-33 expression was reduced in the brains' of patients with Alzheimer’s disease. Cellular models have suggested that this association may be due to the ability of IL-33 to down-regulate A- peptide secretion [11]. A major biological action of this cytokine was recently described as a crucial intracellular nuclear factor with transcriptional regulatory properties associated with Crohn’s disease [12]. All in all, our results showed that there is an association between IL-33 gene polymorphisms and risk of Schizophrenia in our population. However, we suggest that the results of this study be confirmed in further investigations using larger sample size in different populations across the world.


Acknowledgements: We would like to thank the Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran for supporting this project financially.


Conflict of Interest: The authors declare no conflict of interest.

  1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141.
  2. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995;29:141-152.
  3. Fila-Danilow A, Kucia K, Kowalczyk M, Owczarek A, Paul-Samojedny M, Borkowska Suchanek R, Kowalski JP. Association study of interleukin-4 polymorphisms with paranoid schizophrenia in the Polish population: a critical approach. Mol Biol Rep 2012;39:7941-7947.
  4. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010;59:143-160.
  5. Talabot-Ayer, Calo N, Vigne S, Lamacchia C, Gabay C, Palmer G. The mouse interleukin (IL) 33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters. J Leukoc Biol 2012;91:119-125.
  6. Rogala B, Gluck J. The role of interleukin-33 in rhinitis. Curr Allergy Asthma Rep 2013;13:196-202.
  7. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8:22.
  8. Nakae S, Morita H, Ohno T, Arae K, Matsumoto K, Saito H. Role of interleukin-33 in innate-type immune cells in allergy. Allergol Int 2013;62:13-20.
  9. Yu JT, Song JH, Wang ND, Wu ZC, Zhang Q, Zhang N, Zhang W, Xuan SY, Tan L. Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease. Neurobiol Aging 2012;33:e11-14.
  10. Lin CC, Chang CM, Chang PY, Huang TL. Increased interleukin-6 level in Taiwanese schizophrenic patients. Chang Gung Med J 2011;34:375-3781.
  11. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, Maurage CA, Huot L, Bensemain F, Laumet G, Ayral AM, Fievet N, Hauw JJ, DeKosky ST, Lemoine Y, Iwatsubo T, Wavrant-Devrieze F, Dartigues JF, Tzourio C, Buee L, Pasquier F, Berr C, Mann D, Lendon C, Alperovitch A, Kamboh MI, Amouyel P, Lambert JC. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 2009;14:1004-1016.
  12. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205: 339-346.